Narinder Singh
Direttore Tecnico/Scientifico/R&S presso ARCELLX, INC.
Posizioni attive di Narinder Singh
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| ARCELLX, INC. | Direttore Tecnico/Scientifico/R&S | 01/10/2021 | - |
Storia della carriera di Narinder Singh
Precedenti posizioni note di Narinder Singh
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| FORTE BIOSCIENCES, INC. | Direttore Tecnico/Scientifico/R&S | 01/08/2021 | 01/10/2021 |
| AIMMUNE THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 06/07/2020 | 01/07/2021 |
| GENOCEA BIOSCIENCES, INC. | Corporate Officer/Principal | 01/03/2018 | 01/07/2020 |
| MOMENTA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/07/2015 | 01/03/2018 |
Formazione di Narinder Singh
| Indian Institute of Technology New Delhi | Graduate Degree |
| University of Houston | Graduate Degree |
| UCLA Anderson School of Management | Masters Business Admin |
Statistiche
Distribuzione geografica
| Stati Uniti | 8 |
| India | 2 |
Posizioni
| Chief Tech/Sci/R&D Officer | 3 |
| Corporate Officer/Principal | 2 |
| Graduate Degree | 2 |
Settori
| Health Technology | 6 |
| Consumer Services | 4 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| GENOCEA BIOSCIENCES, INC. | Health Technology |
| ARCELLX, INC. | Health Technology |
| FORTE BIOSCIENCES, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Momenta Pharmaceuticals, Inc.
 Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
Aimmune Therapeutics, Inc.
 Aimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA. | Health Technology |
- Borsa valori
- Insiders
- Narinder Singh
- Esperienza
